BVF PARTNERS L P/IL
CIK 1055947 · last filed 2025-07-01
BVF PARTNERS L P/IL is a corporate insider who has filed 56 SEC Form 4 insider transactions across 26 companies since 2008. The most recent filing, for KYMR, was dated Jun 26, 2026. Across all open-market trades the lifetime net is +$77.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.11B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.11B
26
56
$77.38M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 353,412 | $106.16 | $37.52M | $139.55M | 1 | 2025-07-01 |
| PVLA | 282,223 | $142.84 | $40.31M | $0 | 1 | 2024-12-17 | |
| MLTX | Director | 9,005,700 | $18.71 | $168.50M | $0 | 1 | 2024-06-10 |
| ELDN | 10%+ Owner | 3,361,803 | $3.40 | $11.43M | $0 | 1 | 2024-05-13 |
| XOMAP | Director | 1,556,696 | $24.98 | $38.89M | $0 | 1 | 2022-05-20 |
| RAIN | Director | 1,367,838 | $1.32 | $1.81M | $266.23M | 3 | 2022-01-10 |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 1,578,732 | $90.00 | $142.09M | -$290.16M | 3 | 2021-10-08 |
| OLMA | Director | 535,638 | $11.62 | $6.22M | $0 | 1 | 2021-05-26 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 3,279,831 | $0.04 | $146.6K | $1.47M | 2 | 2021-02-19 |
| CTMX | 358,450 | $3.22 | $1.15M | $0 | 1 | 2021-02-18 | |
| XOMA | 10%+ Owner | 2,194,410 | $40.17 | $88.15M | $1.20M | 1 | 2020-08-20 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 346,627 | $38.00 | $13.17M | $4.44M | 1 | 2019-10-25 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 2,734,725 | $9.09 | $24.86M | $8.53M | 2 | 2017-06-14 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 10%+ Owner | 274,882 | — | — | $1.16M | 1 | 2017-06-07 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 10%+ Owner | 3,298,293 | — | — | $5.57M | 2 | 2014-12-17 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 124,580 | — | — | $0 | 1 | 2014-03-25 | |
| PTN | 10%+ Owner | 17,525 | $7.68 | $134.6K | -$5.62M | 2 | 2014-03-03 |
| CCXI | 10%+ Owner | 2,079,532 | $14.52 | $30.19M | $10.51M | 3 | 2013-12-05 |
| LGND | 10%+ Owner | 4,506,145 | $296.28 | $1.34B | -$46.58M | 7 | 2013-01-25 |
| NBIX | 10%+ Owner | 6,658,212 | $182.83 | $1.22B | -$8.66M | 4 | 2012-02-10 |
| ICAGEN INC (ICGN) Delisted | 10%+ Owner | 219,700 | — | — | $4.56M | 1 | 2011-09-09 |
| CAPS | 10%+ Owner | 820 | $0.25 | $204 | $149.9K | 1 | 2011-06-29 |
| Celera CORP (CRA) Delisted | 10%+ Owner | 18,772,784 | — | — | $8.96M | 1 | 2011-04-07 |
| RPRX | 10%+ Owner | 2,297,776 | $59.97 | $137.80M | -$4.03M | 1 | 2009-09-21 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | 855,770 | $15.50 | $13.26M | -$20.11M | 1 | 2009-09-11 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 8,459,999 | — | — | $181.2K | 3 | 2008-12-05 |
Recent Filings
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | KYMR | Notice (144) | −1,630,658 | -$189.91M | EDGAR |
| 2026-03-31 | MLTX | Notice (144) | −3,750,000 | -$63.49M | EDGAR |
| 2025-07-01 | KYMR | Mixed | +3,171,670 | $139.55M | EDGAR |
| 2024-12-17 | PVLA | Other (J) | +4,389,290 | $0 | EDGAR |
| 2024-06-10 | MLTX | Grant (A) | — | $0 | EDGAR |
| 2024-05-13 | ELDN | Buy (P) | +19,279,370 | $0 | EDGAR |
| 2022-05-20 | XOMAP | Grant (A) | — | $0 | EDGAR |
| 2022-01-10 | RAIN | Buy (P) | +5,577,280 | $66.93M | EDGAR |
| 2021-10-08 | Merus N.V. (MRUS) Delisted | Sell (S) | −11,327,140 | -$312.22M | EDGAR |
| 2021-05-26 | OLMA | Other (J) | +995,560 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.